vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update

•

Breakthrough Therapy Designation. As announced in April,the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes. Breakthrough Therapy designation is intended to expedite the development and review of a drug candidate that is planned for the treatment of a serious or life-threatening disease where initial clinical evidence indicates that the drug may demonstrate a substantial improvement over existing therapies on one or more clinically significant endpoints.

•

Mechanistic Study of Ketoacidosis with TTP399. The Company began dosing patients in a mechanistic study of TTP399 in people with type 1 diabetes to determine the impact of TTP399 on ketone body formation during a period of acute insulin withdrawal. vTv expects to report topline results from the mechanistic study in the third quarter of 2021.

•

Pivotal Study Planning. The Company is planning to initiate the first of two pivotal, placebo-controlled, six-month clinical trials of TTP399 in subjects with type 1 diabetes in the fourth quarter of 2021. The current study designs will be shared with the FDA for its input and advice as part of the collaborative process enabled by the Breakthrough Therapy designation.

•

Multiple Ascending Dose Study with HPP737. The Company began dosing healthy subjects in a phase 1 multiple ascending dose study to assess the safety, tolerability, and pharmacokinetic profile of HPP737, an oral PDE4 inhibitor. This phase 1 study is expected to report topline results in the third quarter and will inform dose selection for a planned phase 2 study in psoriasis.

•

Reneo Pharmaceuticals Completes Initial Public Offering. We congratulate our licensee, Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), for successfully completing an initial public offering in April. The Company is party to a license agreement with Reneo for its lead asset REN001, which Reneo is currently developing in three rare genetic diseases: primary mitochondrial myopathies, long-chain fatty acid oxidation disorders, and glycogen storage disease type V (McArdle disease).

•

Cash Position: The Company's cash position as of March 31, 2021, was $8.4 million compared to $5.7 million as of December 31, 2020.

•

Revenue: Revenue for the first quarter of 2021 was $1.0 million and was $6.4 million for the fourth quarter of 2020. The revenue for the first quarter was non-cash and related to the recognition of revenue pertaining to the Huadong license agreement. The revenue for the fourth quarter was primarily attributable to the upfront consideration, consisting of cash and an equity interest, received in connection with the Company's license agreement with Anteris Bio.

•

R&D Expenses: Research and development expenses were $3.1 million and $2.5 million for the three months ended March 31, 2021 and December 31, 2020, respectively. This increase of $0.6 million was driven primarily by the increase in spending for our study of HPP737 in psoriasis.

•

G&A Expenses: General and administrative expenses were consistent between periods at $2.2 million and $2.0 million for the three months ended March 31, 2021 and December 31, 2020, respectively.

•

Net (Loss)/Income Before Non-Controlling Interest: Net loss before non-controlling interest was $5.9 million for the first quarter of 2021 compared to net income of $1.6 million for the fourth quarter of 2020.

•

Net (Loss)/Income Per Share: Diluted net loss per share was ($0.08) for the three months ended March 31, 2021 compared to a diluted net income per share of $0.02 for the three months ended December 31, 2020, based on weighted-average diluted shares of 56.5 million and 74.4 million for the three-month periods ended March 31, 2021 and December 31, 2020, respectively. Non-GAAP net loss per fully exchanged share was ($0.09) for the three months ended March 31, 2021 compared to a net income per fully exchanged share of $0.02 at December 31, 2020, based on non-GAAP fully exchanged weighted-average shares of 79.6 million and 74.4 million for the three months ended March 31, 2021 and December 31, 2020, respectively.

March 31,

December 30,

2021

2020

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$

8,449

$

5,747

Accounts receivable, net

2

158

Prepaid expenses and other current assets

710

939

Current deposits

60

371

Total current assets

9,221

7,215

Property and equipment, net

344

367

Operating lease right-of-use assets

464

482

Long-term investments

6,725

6,725

Total assets

$

16,754

$

14,789

Liabilities, Redeemable Noncontrolling Interest and Stockholders' Deficit

Current liabilities:

Accounts payable and accrued expenses

$

4,965

$

6,120

Operating lease liabilities

162

155

Current portion of contract liabilities

35

31

Current portion of notes payable

-

84

Total current liabilities

5,162

6,390

Contract liabilities, net of current portion

18

1,009

Operating lease liabilities, net of current portion

633

676

Warrant liability, related party

4,519

2,871

Other liabilities

50

50

Total liabilities

10,382

10,996

Commitments and contingencies

Redeemable noncontrolling interest

62,647

83,895

Stockholders' deficit:

Class A Common Stock

576

541

Class B Common Stock

232

232

Additional paid-in capital

217,647

209,161

Accumulated deficit

(274,730

)

(290,036

)

Total stockholders' deficit attributable to vTv Therapeutics Inc.

(56,275

)

(80,102

)

Total liabilities, redeemable noncontrolling interest and stockholders' deficit

$

16,754

$

14,789

Three Months Ended

March 31, 2021

December 31, 2020

Revenue

$

987

$

6,399

Operating expenses:

Research and development

3,103

2,534

General and administrative

2,164

2,035

Total operating expenses

5,267

4,569

Operating (loss)/income

(4,280

)

1,830

Interest income

1

-

Interest expense

-

(67

)

Other expense, net

(1,648

)

(156

)

Loss before income taxes and noncontrolling interest

(5,927

)

1,607

Income tax provision

15

-

Net loss before noncontrolling interest

(5,942

)

1,607

Less: net (loss)/income attributable to noncontrolling interest

(1,701

)

481

Net (loss)/income attributable to vTv Therapeutics Inc.

$

(4,241

)

$

1,126

Net (loss)/income attributable to vTv Therapeutics Inc. common shareholders

$

(4,241

)

$

1,126

Net (loss)/income per share:

Basic net (loss)/income per share of vTv Therapeutics Inc. Class A

Common Stock

$

(0.08

)

$

0.02

Diluted net (loss)/income per share of vTv Therapeutics Inc. Class A

Common Stock

$

(0.08

)

$

0.02

Weighted average shares used in calculating:

Basic net (loss)/income per share of vTv Therapeutics Inc. Class A

Common Stock

56,472,535

51,133,609

Diluted net (loss)/income per share of vTv Therapeutics Inc. Class A

Common Stock

56,472,535

74,397,085

Three Months Ended March 31,

2021

2020

(Unaudited)

Revenue

$

987

$

8

Operating expenses:

Research and development

3,103

4,204

General and administrative

2,164

2,450

Total operating expenses

5,267

6,654

Operating loss

(4,280

)

(6,646

)

Interest income

1

12

Interest expense

-

(168

)

Other expense, net

(1,648

)

(363

)

Loss before income taxes and noncontrolling interest

(5,927

)

(7,165

)

Income tax provision

15

-

Net loss before noncontrolling interest

(5,942

)

(7,165

)

Less: net loss attributable to noncontrolling interest

(1,701

)

(2,441

)

Net loss attributable to vTv Therapeutics Inc.

$

(4,241

)

$

(4,724

)

Net loss attributable to vTv Therapeutics Inc. common shareholders

$

(4,241

)

$

(4,724

)

Net loss per share of vTv Therapeutics Inc. Class A Common

Stock, basic and diluted

$

(0.08

)

$

(0.11

)

Weighted-average number of vTv Therapeutics Inc. Class A

Common Stock, basic and diluted

56,472,535

43,462,551

Three Months Ended

March 31, 2021

December 30, 2020

Numerator:

Net (loss)/income attributable to vTv Therapeutics Inc. common shareholders

$

(4,241

)

$

1,126

Other expense - related party

(1,648

)

(156

)

Share-based compensation expense

436

272

Reallocation of net income attributable to noncontrolling

interest from the assumed exchange of Class B shares ⁽¹⁾

(1,701

)

481

Adjusted net (loss)/income before noncontrolling interest

$

(7,154

)

$

1,723

Denominator:

Weighted-average number of vTv Therapeutics Inc.

Class A Common Stock, diluted

56,472,535

74,397,085

Assumed exchange of Class B Common Stock ⁽¹⁾

23,094,137

-

Adjusted proforma fully exchanged weighted-average

shares of Class A common stock outstanding, diluted

79,566,672

74,397,085

Adjusted net (loss)/income per fully exchanged share, diluted

$

(0.09

)

$

0.02

Three Months Ended March 31,

2021

2020

Numerator:

Net loss attributable to vTv Therapeutics Inc. common shareholders

$

(4,241

)

$

(4,724

)

Other expense - related party

(1,648

)

(363

)

Share-based compensation expense

436

380

Reallocation of net income attributable to noncontrolling

interest from the assumed exchange of Class B shares ⁽¹⁾

(1,701

)

(2,441

)

Adjusted net loss before noncontrolling interest

$

(7,154

)

$

(7,148

)

Denominator:

Weighted-average number of vTv Therapeutics Inc.

Class A Common Stock, diluted

56,472,535

43,462,551

Assumed exchange of Class B Common Stock ⁽¹⁾

23,094,137

23,094,221

Adjusted proforma fully exchanged weighted-average

shares of Class A common stock outstanding,

diluted

79,566,672

66,556,772

Adjusted net loss per fully exchanged share,

diluted

$

(0.09

)

$

(0.11

)

(1)

Assumes the exchange of all outstanding Class B common stock, resulting in the inclusion of shares of Class B common stock in the weighted average share count, if not already considered, and the elimination of the noncontrolling interest and recognition of the net income attributable to noncontrolling interests.